Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 7/20 | 0.61 |
| ▸ | STAT3 | P40763 | 8/20 | 0.41 |
| ▸ | XDH | P47989 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18330542 | 0.92 | HSP90AA1 (0.73) | HSP90AA1STAT3XDH | |
| SCHEMBL22360998 | 0.92 | HSP90AA1 (0.73) | HSP90AA1STAT3XDH | |
| SCHEMBL18319489 | 0.92 | HSP90AA1 (0.73) | HSP90AA1STAT3XDH | |
| Verproside SCHEMBL31619362 | 0.80 | HSP90AA1 (0.83) | HSP90AA1XDHPTPN1 | |
| Verproside SCHEMBL2449966 | 0.80 | HSP90AA1 (0.83) | HSP90AA1XDHPTPN1 | |
| SCHEMBL22360997 | 0.76 | HSP90AA1 (0.48) | HSP90AA1STAT3XDH | |
| Picroside Ii SCHEMBL24209283 | 0.75 | HSP90AA1 (0.78) | HSP90AA1XDH | |
| Picroside Ii SCHEMBL29367651 | 0.75 | HSP90AA1 (0.78) | HSP90AA1XDH | |
| Picroside Ii SCHEMBL29425971 | 0.75 | HSP90AA1 (0.78) | HSP90AA1XDH | |
| Picroside Ii SCHEMBL24209282 | 0.75 | HSP90AA1 (0.78) | HSP90AA1XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216462-A1 | PHARMACEUTICAL COMPOSITION FOR ENHANCING IMMUNITY OR ANTI-CANCER ACTIVITY INCLUDING EXTRACT OF PSEUDOLYSIMACHION NAKAIANUM (OHWI) T.YAMAZ AS ACTIVE INGREDIENT | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2024-07-04 | — | — | US | disclosed |
| US-20240216462-A1 | PHARMACEUTICAL COMPOSITION FOR ENHANCING IMMUNITY OR ANTI-CANCER ACTIVITY INCLUDING EXTRACT OF PSEUDOLYSIMACHION NAKAIANUM (OHWI) T.YAMAZ AS ACTIVE INGREDIENT | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2024-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216462-A1 | PHARMACEUTICAL COMPOSITION FOR ENHANCING IMMUNITY OR ANTI-CANCER ACTIVITY INCLUDING EXTRACT OF PSEUDOLYSIMACHION NAKAIANUM (OHWI) T.YAMAZ AS ACTIVE INGREDIENT | CD4, IL17A, ICOS | HSP90AA1 1789/4885STAT3 44/4885XDH 3209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.